Eber B, Schumacher M, Zweiker R, Pokan R, Klein W
Medizinischen Universitätsklinik Graz.
Acta Med Austriaca. 1992;19(5):137-9.
Nisoldipine represents a new attractive second generation calcium channel blocker of the dihydropyridine-class for the treatment of all types of coronary artery disease. The effect on chronic ischemia is comparable to long-acting nitrates, side-effects have been rarely observed. The advantages will be the high vascular selectivity with only slight negative inotropic effect as well as a long-lasting positive influence on the myocardial metabolism. Up to now, no studies have been reported which compare nisoldipine and long-acting nitrates directly, but this calcium antagonist appears to influence duration and intensity of symptomatic and silent episodes of ischemia similar to the nitrates.
尼索地平是一种新型且有吸引力的第二代二氢吡啶类钙通道阻滞剂,用于治疗各类冠状动脉疾病。其对慢性缺血的疗效与长效硝酸盐类药物相当,且很少观察到副作用。优势在于具有高度的血管选择性,仅有轻微的负性肌力作用,以及对心肌代谢有持久的积极影响。到目前为止,尚未有直接比较尼索地平和长效硝酸盐类药物的研究报道,但这种钙拮抗剂似乎对缺血性症状发作和无症状发作的持续时间及强度的影响与硝酸盐类药物相似。